BioCentury | Jul 10, 2020
Finance

$30M series A will propel Tranquis to the clinic with its neuroinflammation candidate

...Hillsborough Venture, Correlation Ventures and other undisclosed investors. Tranquis plans to first test lead candidate TQS-168...
...vivo and in vitro data so far support the role of neuroinflammation in disease, and TQS-168’s...
...correct that inflammation. When myeloid cells derived from patients with neurodegenerative diseases were incubated with TQS-168...
Items per page:
1 - 1 of 1